SIMULATION MODEL OF IBRUTINIB IN TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)

被引：3
|
作者：
Peng, S. [1 ]
Sorensen, S. [1 ]
Pan, F. [1 ]
Dorman, E. [1 ]
Sun, S. [2 ]
Van Sanden, S. [3 ]
Sengupta, N. [4 ]
Gaudig, M. [5 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Janssen, Raritan, NJ USA
[3] Univ Hosp Leuven, Leuven, Belgium
[4] Janssen Pharmaceut Inc, Raritan, NJ USA
[5] Janssen Pharmaceut Inc, Neuss, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2196
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN38
引用
收藏
页码：A620 / A620
页数：1
相关论文
共 50 条
  • [31] Ibrutinib for the Treatment of Mantle Cell Lymphoma
    Herrera, Alex F.
    Jacobsen, Eric D.
    CLINICAL CANCER RESEARCH, 2014, 20 (21) : 5365 - 5371
  • [32] Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
    Wang, Michael
    Schuster, Stephen J.
    Phillips, Tycel
    Lossos, Izidore S.
    Goy, Andre
    Rule, Simon
    Hamadani, Mehdi
    Ghosh, Nilanjan
    Reeder, Craig B.
    Barnett, Evelyn
    Bravo, Marie-Laure Casadebaig
    Martin, Peter
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [33] Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
    Michael Wang
    Stephen J. Schuster
    Tycel Phillips
    Izidore S. Lossos
    Andre Goy
    Simon Rule
    Mehdi Hamadani
    Nilanjan Ghosh
    Craig B. Reeder
    Evelyn Barnett
    Marie-Laure Casadebaig Bravo
    Peter Martin
    Journal of Hematology & Oncology, 10
  • [34] Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience
    Jeon, Young-Woo
    Yoon, Seugyun
    Min, Gi June
    Park, Sung-Soo
    Park, Silvia
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Min, Chang-Ki
    Lee, Jong Wook
    Cho, Seok-Goo
    CANCER MEDICINE, 2019, 8 (16): : 6860 - 6870
  • [35] Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study
    Wang, Michael
    Martin, Peter
    Phillips, Tycel
    Goy, Andre
    Lossos, Izidore S.
    Rule, Simon A.
    Hamadani, Mehdi
    Ghosh, Nilanjan
    Reeder, Craig B.
    Barnett, Evelyn
    Bravo, Marie-Laure Casadebaig
    Schuster, Stephen J.
    BLOOD, 2016, 128 (22)
  • [36] Ibrutinib as bridge therapy to allogeneic stem cell transplantation in refractory mantle cell lymphoma (MCL): A case report
    Grillo, G.
    Zucchetti, E.
    Zilioli, V. R.
    Rusconi, C.
    Forno, B.
    Zancanella, M.
    Meli, E.
    Minga, P.
    Cairoli, R.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S169 - S169
  • [37] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [38] Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Alrawashdh, Neda
    Alkhatib, Nimer
    McBride, Ali
    Persky, Daniel
    Abraham, Ivo
    BLOOD, 2018, 132
  • [39] Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Martin, Peter
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ferrante, Lucille
    Reddy, Vijay
    Londhe, Anil
    Wildgust, Mark
    McGowan, Tracy
    Bartlett, Nancy L.
    BLOOD, 2014, 124 (21)
  • [40] SAKK 36/13-Ibrutinib and bortezomib and ibrutinib maintenance for relapsed/refractory mantle cell lymphoma: an ongoing trial
    Novak, U.
    Fehr, M.
    Zander, T.
    Winterhalder, R.
    Amram, M.
    Stathis, A.
    Rondeau, S.
    Vilei, S. Berardi
    Eckhardt, K.
    Driessen, C.
    Renner, C.
    SWISS MEDICAL WEEKLY, 2018, 148 : 2S - 2S
12345